-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B5WsF4DYlST5zieKT+tPp9zZLcWk1XQvPCr2Ascjo/IxCLaQ9ilwMRNg9zp8T/nD PupFaCoOJ/j8H7GMhwM1SA== 0000882377-07-002424.txt : 20071030 0000882377-07-002424.hdr.sgml : 20071030 20071030172145 ACCESSION NUMBER: 0000882377-07-002424 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20071030 DATE AS OF CHANGE: 20071030 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Ahmed Mohamed CENTRAL INDEX KEY: 0001416933 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: BUSINESS PHONE: 971504559533 MAIL ADDRESS: STREET 1: PO BOX 33280 CITY: DUBAI STATE: C0 ZIP: 0 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CALYPTE BIOMEDICAL CORP CENTRAL INDEX KEY: 0000899426 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 061226727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-50235 FILM NUMBER: 071200457 BUSINESS ADDRESS: STREET 1: 5000 HOPYARD ROAD, SUITE 480 CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: 9257307200 MAIL ADDRESS: STREET 1: 5000 HOPYARD ROAD, SUITE 480 CITY: PLEASANTON STATE: CA ZIP: 94588 SC 13G 1 p07-1063_sch13gahmed.htm CALYPTE BIOMEDICAL CORP. Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
SCHEDULE 13G
Under the Securities Exchange Act of 1934

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
 PURSUANT TO RULE 13d-2

(Amendment No. …)*

 
CALYPTE BIOMEDICAL CORP.
 (Name of Issuer)


COMMON STOCK, $0.03 PAR VALUE PER SHARE
 (Title of Class of Securities)
 
 
131722100
(CUSIP Number)
 
 
March 28, 2007
 (Date of Event which Requires Filing of this Statement)
 

Check the appropriate box to designate the rule pursuant to which the Schedule is filed:
 
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 ( the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 

 
CUSIP No. 131722100
SCHEDULE 13G
Page 2 of 5 Pages
 
 
1
NAME OF REPORTING PERSON:  Mohamed Ahmed
   
 
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only):
   
   
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP            (a) o
 
(see instructions)                                                                                                                        (b) x
   
3
SEC USE ONLY
   
4
CITIZENSHIP OR PLACE OF ORGANIZATION
   
 
Switzerland
 
 
NUMBER OF
5
 SOLE VOTING POWER
 
SHARES
   55,000,000
 
BENEFICIALLY
    
 
OWNED BY
6
SHARED VOTING POWER
 
EACH
   0
 
REPORTING
    
 
PERSON
7
 SOLE DISPOSITIVE POWER
 
WITH
   55,000,000
       
   
8
 SHARED DISPOSITIVE POWER
      0
       
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
 
55,000,000
   
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
 
EXCLUDES CERTAIN SHARES (see instructions)                o
   
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
 
14.7% of outstanding shares of common stock, $0.03 par value per share as of August 10, 2007.
   
12
TYPE OF REPORTING PERSON (see instructions)
   
 
IN
 
 
 
CUSIP No. 131722100
SCHEDULE 13G
Page 3 of 5 Pages
 
 
 
Statement for Schedule 13G
 
This initial Schedule 13G is being filed by Mohamed Ahmed, an individual, and a citizen of Switzerland, with respect to the common stock, $0.03 par value per share (the “Common Stock”), of Calypte Biomedical Corp., a Delaware corporation (the “Company”).
 
Item 1(a).  Name of Issuer
 
Calypte Biomedical Corp.

Item 1(b).  Address of Issuer’s Principal Executive Offices
 
5 Centerpointe Drive, Suite 400
Lake Oswego, OR  97035

Item 2(a).  Name of Person Filing
 
Mohamed Ahmed

Item 2(b).  Address or Principal Business Office, or, if None, Residence
 
Mohamed Ahmed
P.O. Box 33280
Dubai
United Arab Emirates
 
Item 2(c).  Citizenship
 
Switzerland
 
Item 2(d).  Title of Class of Securities
 
Common stock, $0.03 par value per share
 
Item 2(e).  CUSIP No.
 
131722100
 
Item 3.  Classification of Person Filing, If Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c)
 
N/A.  Filed pursuant to §240.13d-1(c)
 
 
 
CUSIP No. 131722100
SCHEDULE 13G
Page 4 of 5 Pages
 
Item 4.  Ownership
 
The following information with respect to Mr. Ahmed’ s ownership of the Common Stock of the Company is provided as of August 10, 2007.
 
(a) Amount Beneficially Owned
55,000,000
   
(b) Percent of Class
14.7%
   
(c) Number of shares as to which such person has:
  
   
    (i)   sole power to vote or to direct the vote
55,000,000
   
    (ii)  shared power to vote or to direct the vote 
0
   
    (iii) sole power to dispose or to direct disposition of 
55,000,000
   
    (iv)  shared power to dispose or to direct disposition of
0

Item 5.  Ownership of 5% or Less of a Class

N/A

Item 6.  Ownership of More than 5% on Behalf of Another Person

N/A

Item 7.  Identification and Classification of Acquiring Subsidiary

N/A

Item 8.  Identification and Classification of Members of the Group

N/A

Item 9.  Notice of Dissolution of Group

N/A
 
 
CUSIP No. 131722100
SCHEDULE 13G
Page 5 of 5 Pages
 
Item 10.  Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 

 
SIGNATURES
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
 
 
October 30, 2007
(Date)


          /s/ Mohamed Ahmed
    MOHAMED AHMED                                     

-----END PRIVACY-ENHANCED MESSAGE-----